Cambridge Debuts $10 Photonic Lab-on-Chip Spectrometer

University of Cambridge researchers have developed a $10, centimetre-scale optical convolutional spectrometer that matches laboratory-grade precision, opening substantial new wearable biomarker monitoring territory. Published in Nature Photonics on 22 October 2026, the silicon nitride photonic platform demonstrated non-invasive glucose, lactate and alcohol monitoring applications alongside industrial quality control use cases, challenging commercial benchtop instrument economics.

 The device applies the convolution theorem directly to incoming light using repeating optical components (unbalanced Mach-Zehnder interferometers or micro-ring resonators) on a silicon nitride photonic platform, with Fast Fourier transforms recovering the spectrum. Working across near-infrared wavelengths of 1200-1700nm with processing times under one second, the system operates reliably from -20°C to 80°C and achieved 100% classification success for plastics, pharmaceuticals, coffee, flour and tea in reported tests. Solution concentration accuracy of around 0.01% exceeded commercial benchtop instruments in those experiments. Lead author Chunhui Yao, project lead Qixiang Cheng and Richard Penty led the integration work, which involved GlitterinTech, a startup spun out of the same research group.

Non-invasive glucose tracking was demonstrated over an extended period in one participant, alongside skin moisture, blood alcohol and lactate measurement. The commercial opportunity directly challenges incumbent continuous glucose monitoring (CGM) specialists Abbott (FreeStyle Libre), Dexcom (G7, Stelo) and Medtronic (Guardian) with a non-invasive alternative, while sharpening competitive dynamics across the broader optical spectrometer category dominated by Thermo Fisher Scientific, Bruker, Agilent, Shimadzu and PerkinElmer. The wearable biomarker application overlaps with consumer health platforms Apple Health, Oura Ring, Whoop and emerging continuous metabolic health specialists Levels and Signos. GlitterinTech represents commercial translation vehicle for the Cambridge spin-out.

The commercial signal is a potentially category-defining low-cost photonic diagnostic platform where lab-on-chip economics challenge both benchtop analytical instruments and invasive CGM technology, with substantial wearable biomarker opportunity. Further validation is required before clinical deployment. Expect Abbott, Dexcom, Medtronic, Thermo Fisher Scientific, Agilent, Shimadzu, Apple and Oura to monitor Cambridge photonic spectrometer development through 2027 and 2028.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact Amelia Phillips today!